Literature DB >> 1420147

Mammalian DNA polymerase beta: characterization of a 16-kDa transdomain fragment containing the nucleic acid-binding activities of the native enzyme.

J R Casas-Finet1, A Kumar, R L Karpel, S H Wilson.   

Abstract

The 39-kDa DNA polymerase beta (beta-Pol) molecule can be readily converted into two constituent domains by mild proteolysis; these domains are represented in an 8-kDa N-terminal fragment and a 31-kDa C-terminal fragment [Kumar et al. (1990a) J. Biol. Chem. 265, 2124-2131]. Intact beta-Pol is a sequence-nonspecific nucleic acid-interactive protein that binds both double-stranded (ds) and single-stranded (ss) polynucleotides. These two activities appear to be contributed by separate portions of the enzyme, since the 31-kDa domain binds ds DNA but not ss DNA, and conversely, the 8-kDa domain binds ss DNA but not ds DNA [Casas-Finet et al. (1991) J. Biol. Chem. 266, 19618-19625]. Truncation of the 31-kDa domain at the N-terminus with chymotrypsin, to produce a 27-kDa fragment (residues 140-334), eliminated all DNA-binding activity. This suggested that the ds DNA-binding capacity of the 31-kDa domain may be carried in the N-terminal segment of the 31-kDa domain. We used CNBr to prepare a 16-kDa fragment (residues 18-154) that spans the ss DNA-binding region of the 8-kDa domain along with the N-terminal portion of the 31-kDa domain. The purified 16-kDa fragment was found to have both ss and ds polynucleotide-binding capacity. Thermodynamic binding properties for these activities are similar to those of the intact enzyme.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1420147     DOI: 10.1021/bi00157a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Characterization of DNA polymerase beta splicing variants in gastric cancer: the most frequent exon 2-deleted isoform is a non-coding RNA.

Authors:  Valeria Simonelli; Mariarosaria D'Errico; Domenico Palli; Rajendra Prasad; Samuel H Wilson; Eugenia Dogliotti
Journal:  Mutat Res       Date:  2009-07-25       Impact factor: 2.433

2.  Domain specific interaction in the XRCC1-DNA polymerase beta complex.

Authors:  A Marintchev; A Robertson; E K Dimitriadis; R Prasad; S H Wilson; G P Mullen
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

3.  A variant of DNA polymerase beta acts as a dominant negative mutant.

Authors:  N Bhattacharyya; S Banerjee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

Review 4.  Base excision repair and design of small molecule inhibitors of human DNA polymerase β.

Authors:  Samuel H Wilson; William A Beard; David D Shock; Vinod K Batra; Nisha A Cavanaugh; Rajendra Prasad; Esther W Hou; Yuan Liu; Kenjiro Asagoshi; Julie K Horton; Donna F Stefanick; Padmini S Kedar; Michael J Carrozza; Aya Masaoka; Michelle L Heacock
Journal:  Cell Mol Life Sci       Date:  2010-09-16       Impact factor: 9.261

5.  Human DNA polymerase beta mutations allowing efficient abasic site bypass.

Authors:  Sonja Gieseking; Konrad Bergen; Francesca Di Pasquale; Kay Diederichs; Wolfram Welte; Andreas Marx
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

6.  Dominant negative rat DNA polymerase beta mutants interfere with base excision repair in Saccharomyces cerevisiae.

Authors:  C A Clairmont; J B Sweasy
Journal:  J Bacteriol       Date:  1996-02       Impact factor: 3.490

7.  Specific inhibition of DNA polymerase beta by its 14 kDa domain: role of single- and double-stranded DNA binding and 5'-phosphate recognition.

Authors:  I Husain; B S Morton; W A Beard; R K Singhal; R Prasad; S H Wilson; J M Besterman
Journal:  Nucleic Acids Res       Date:  1995-05-11       Impact factor: 16.971

8.  Detection and characterization of mammalian DNA polymerase beta mutants by functional complementation in Escherichia coli.

Authors:  J B Sweasy; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.